Publications by Johan Bodegård
85 publications found
Original articles
Are there lost opportunities in chronic kidney disease? A region-wide cohort study
BMJ Open, 14 (4), e074064
DOI 10.1136/bmjopen-2023-074064, PubMed 38643002
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction
J Am Heart Assoc, 13 (8), e032257
DOI 10.1161/JAHA.123.032257, PubMed 38591322
Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort
ESC Heart Fail (in press)
DOI 10.1002/ehf2.14685, PubMed 38311878
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD)
Kidney360, 5 (3), 352-362
DOI 10.34067/KID.0000000000000374, PubMed 38297439
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF
JACC Heart Fail, 11 (10), 1320-1332
DOI 10.1016/j.jchf.2023.04.017, PubMed 37354145
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case-control study
BMJ Open, 13 (4), e069037
DOI 10.1136/bmjopen-2022-069037, PubMed 37117003
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Heart, 109 (7), 548-556
DOI 10.1136/heartjnl-2022-321702, PubMed 36781285
Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
Cardiovasc Diabetol, 21 (1), 282
DOI 10.1186/s12933-022-01719-x, PubMed 36522650
Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)
JACC Heart Fail, 11 (1), 1-14
DOI 10.1016/j.jchf.2022.08.009, PubMed 36202739
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
Lancet Reg Health Eur, 20, 100438
DOI 10.1016/j.lanepe.2022.100438, PubMed 36090671
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
Cardiovasc Diabetol, 21 (1), 104
DOI 10.1186/s12933-022-01521-9, PubMed 35689214
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Diabetes Obes Metab, 24 (7), 1277-1287
DOI 10.1111/dom.14698, PubMed 35322567
The Oslo Ischaemia Study: cohort profile
BMJ Open, 11 (10), e049111
DOI 10.1136/bmjopen-2021-049111, PubMed 34645662
Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure
J Hypertens, 39 (10), 2022-2029
DOI 10.1097/HJH.0000000000002894, PubMed 34102659
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
Cardiovasc Diabetol, 20 (1), 159
DOI 10.1186/s12933-021-01345-z, PubMed 34332558
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Eur J Heart Fail, 23 (9), 1499-1511
DOI 10.1002/ejhf.2271, PubMed 34132001
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
Diabetes Obes Metab, 23 Suppl 2, 19-27
DOI 10.1111/dom.14119, PubMed 33835641
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
Diabetes Care, 44 (5), 1211-1218
DOI 10.2337/dc20-2839, PubMed 33653822
Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015
Prim Care Diabetes, 15 (2), 262-268
DOI 10.1016/j.pcd.2020.09.006, PubMed 33032936
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Diabetes Obes Metab, 23 (1), 75-85
DOI 10.1111/dom.14189, PubMed 32893440
Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study
J Diabetes Investig, 12 (1), 67-73
DOI 10.1111/jdi.13321, PubMed 32530554
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Lancet Diabetes Endocrinol, 8 (7), 606-615
DOI 10.1016/S2213-8587(20)30130-3, PubMed 32559476
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Diabetes Obes Metab, 22 (9), 1607-1618
DOI 10.1111/dom.14074, PubMed 32363737
Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men
Stroke, 51 (5), 1435-1441
DOI 10.1161/STROKEAHA.119.027233, PubMed 32268850
Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men
Hypertension, 75 (1), 44-50
DOI 10.1161/HYPERTENSIONAHA.119.13528, PubMed 31735088
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
Diabetes Obes Metab, 21 (12), 2651-2659
DOI 10.1111/dom.13852, PubMed 31379124
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up
J Hypertens, 37 (5), 949-955
DOI 10.1097/HJH.0000000000001959, PubMed 30325341
Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
BMJ Open, 9 (4), e027199
DOI 10.1136/bmjopen-2018-027199, PubMed 30948612
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Diabetes Obes Metab, 21 (5), 1136-1145
DOI 10.1111/dom.13627, PubMed 30609272
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
Diabetes Obes Metab, 21 (4), 968-974
DOI 10.1111/dom.13612, PubMed 30537226
Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men
Stroke, 50 (1), 155-161
DOI 10.1161/STROKEAHA.118.021798, PubMed 30580727
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014
Pharmacoecon Open, 2 (4), 393-402
DOI 10.1007/s41669-017-0063-y, PubMed 29623637
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Endocrinol Diabetes Metab, 1 (4), e00036
DOI 10.1002/edm2.36, PubMed 30815564
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630
Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men
BMC Pulm Med, 18 (1), 118
DOI 10.1186/s12890-018-0655-z, PubMed 30021542
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
J Am Coll Cardiol, 71 (22), 2497-2506
DOI 10.1016/j.jacc.2018.01.085, PubMed 29852973
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Diabetes Obes Metab, 20 (8), 1983-1987
DOI 10.1111/dom.13299, PubMed 29569378
Long-term predictors of stroke in healthy middle-aged men
Int J Stroke, 13 (3), 292-300
DOI 10.1177/1747493017730760, PubMed 28929941
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Diabetes Obes Metab, 20 (2), 344-351
DOI 10.1111/dom.13077, PubMed 28771923
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Lancet Diabetes Endocrinol, 5 (9), 709-717
DOI 10.1016/S2213-8587(17)30258-9, PubMed 28781064
Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden
Prim Care Diabetes, 11 (3), 217-225
DOI 10.1016/j.pcd.2017.03.001, PubMed 28389199
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Circulation, 136 (3), 249-259
DOI 10.1161/CIRCULATIONAHA.117.029190, PubMed 28522450
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Diabetes Obes Metab, 19 (6), 831-841
DOI 10.1111/dom.12889, PubMed 28116795
Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men
Blood Press, 26 (4), 229-236
DOI 10.1080/08037051.2017.1291276, PubMed 28276720
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Diabetes Res Clin Pract, 123, 199-208
DOI 10.1016/j.diabres.2016.12.004, PubMed 28056431
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice
Prim Care Diabetes, 11 (2), 184-192
DOI 10.1016/j.pcd.2016.11.002, PubMed 27894781
Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy Middle-Aged Men: a 28-Year Follow-Up Study
J Am Heart Assoc, 5 (12)
DOI 10.1161/JAHA.116.004555, PubMed 27881424
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Diabetologia, 59 (8), 1692-701
DOI 10.1007/s00125-016-3971-y, PubMed 27189067
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study
Am Heart J, 178, 85-94
DOI 10.1016/j.ahj.2016.05.005, PubMed 27502855
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Diabetes Res Clin Pract, 117, 39-47
DOI 10.1016/j.diabres.2016.04.055, PubMed 27329021
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Clin Drug Investig, 36 (3), 225-33
DOI 10.1007/s40261-015-0372-9, PubMed 26718960
Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients
Ther Adv Psychopharmacol, 5 (1), 13-21
DOI 10.1177/2045125314560740, PubMed 25653826
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
Prim Care Diabetes, 9 (5), 330-7
DOI 10.1016/j.pcd.2015.01.001, PubMed 25631469
Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study
Cardiovasc Diabetol, 14, 5
DOI 10.1186/s12933-014-0170-3, PubMed 25589001
Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden
Value Health, 17 (7), A338
DOI 10.1016/j.jval.2014.08.660, PubMed 27200610
Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study
Eur J Prev Cardiol, 23 (1), 59-66
DOI 10.1177/2047487314553202, PubMed 25281482
Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study
Bipolar Disord, 17 (1), 76-85
DOI 10.1111/bdi.12234, PubMed 25056132
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients
J Hum Hypertens, 28 (11), 663-9
DOI 10.1038/jhh.2014.43, PubMed 25211055
Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients
J Hypertens, 31 (8), 1603-10
DOI 10.1097/HJH.0b013e32836123aa, PubMed 23625112
Low heart rates predict incident atrial fibrillation in healthy middle-aged men
Circ Arrhythm Electrophysiol, 6 (4), 726-31
DOI 10.1161/CIRCEP.113.000267, PubMed 23873309
Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients
Diabetes Metab, 39 (4), 306-13
DOI 10.1016/j.diabet.2013.05.004, PubMed 23871502
Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns
J Intern Med, 274 (4), 371-80
DOI 10.1111/joim.12103, PubMed 23800296
Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Diabetes Res Clin Pract, 101 (2), 201-9
DOI 10.1016/j.diabres.2013.06.001, PubMed 23827210
Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men
Hypertension, 61 (5), 1134-40
DOI 10.1161/HYPERTENSIONAHA.111.00793, PubMed 23529164
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men
Am J Cardiol, 110 (3), 425-32
DOI 10.1016/j.amjcard.2012.03.043, PubMed 22579085
Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk
Eur J Prev Cardiol, 20 (4), 541-8
DOI 10.1177/2047487312444370, PubMed 22492865
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study
Hypertension, 59 (2), 198-204
DOI 10.1161/HYPERTENSIONAHA.111.179713, PubMed 22252392
Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men
J Intern Med, 271 (6), 581-8
DOI 10.1111/j.1365-2796.2011.02480.x, PubMed 22061296
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
Atherosclerosis, 220 (1), 250-6
DOI 10.1016/j.atherosclerosis.2011.10.009, PubMed 22062589
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan
J Clin Hypertens (Greenwich), 13 (3), 189-97
DOI 10.1111/j.1751-7176.2010.00410.x, PubMed 21366850
Health-care costs of losartan and candesartan in the primary treatment of hypertension
J Hum Hypertens, 25 (2), 130-6
DOI 10.1038/jhh.2010.36, PubMed 20376078
Interaction between inflammation and blood viscosity predicts cardiovascular mortality
Scand Cardiovasc J, 44 (2), 107-12
DOI 10.1080/14017430903171248, PubMed 19670036
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
J Hum Hypertens, 24 (4), 263-73
DOI 10.1038/jhh.2009.77, PubMed 19890371
[Long term prognosis in relation to the presence of systolic heart murmurs in healthy middle-aged men]
Tidsskr Nor Laegeforen, 125 (9), 1157-8
PubMed 15880150
Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years
Eur Heart J, 26 (14), 1394-401
DOI 10.1093/eurheartj/ehi278, PubMed 15855193
Symptom-limited exercise testing, ST depressions and long-term coronary heart disease mortality in apparently healthy middle-aged men
Eur J Cardiovasc Prev Rehabil, 11 (4), 320-7
DOI 10.1097/01.hjr.0000136460.57921.46, PubMed 15292766
Possible angina detected by the WHO angina questionnaire in apparently healthy men with a normal exercise ECG: coronary heart disease or not? A 26 year follow up study
Heart, 90 (6), 627-32
DOI 10.1136/hrt.2003.012542, PubMed 15145862
Exercise testing of healthy men in a new perspective: from diagnosis to prognosis
Eur Heart J, 25 (11), 978-86
DOI 10.1016/j.ehj.2004.04.009, PubMed 15172470
[Exercise ECG]
Tidsskr Nor Laegeforen, 124 (3), 339-41
PubMed 14963507
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure
J Hypertens, 21 (7), 1383-9
DOI 10.1097/00004872-200307000-00029, PubMed 12817188
Early versus late morning measurement of blood pressure in healthy men. A potential source of measurement bias?
Blood Press, 11 (6), 366-70
DOI 10.1080/080370502321095339, PubMed 12523680
Other articles
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Diabetes Care, 41 (6), e104-e105
DOI 10.2337/dc18-0339, PubMed 29784707
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
Circulation, 137 (9), 989-991
DOI 10.1161/CIRCULATIONAHA.117.031847, PubMed 29483180
Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al
Circ Arrhythm Electrophysiol, 6 (6), e102
DOI 10.1161/CIRCEP.113.001154, PubMed 24347602
Theses
Cardiovascular long term risk and exercise test findings: 2014 apparently healthy middle aged men followed for 26 years
University of Oslo, Faculty of Medicine, [Oslo], 1 b. (flere pag.)
BIBSYS 060926953, ISBN 82-8072-672-1